Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Brokerages

Key Points

• Analysts rate Oncobiologics “Hold” on average: Seven firms include four hold, two buy and one sell rating, with an average 12-month price target of $4.65.
• The company reported a quarterly loss of $0.09 per share, slightly worse than the $0.08 consensus, while revenue of roughly $10,000 fell far short of the $970,000 estimate.
• Potential catalysts include FDA approval of LYTENAVA and substantial insider buying, but the company’s $55 million stock-and-warrant offering creates significant dilution and has added selling pressure.

Shares of Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average rating of "Hold" by the seven research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $4.65.

A number of equities research analysts have commented on OTLK shares. Wall Street Zen lowered Oncobiologics from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings upgraded Oncobiologics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday. BTIG Research reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Oncobiologics in a research note on Friday. HC Wainwright upped their target price on Oncobiologics to $1.60 and gave the company a "neutral" rating in a report on Monday, July 27th. Finally, Ascendiant Capital Markets increased their target price on shares of Oncobiologics from $6.00 to $10.00 and gave the company a "buy" rating in a research report on Thursday, June 11th.

Oncobiologics Stock Performance

Shares of NASDAQ:OTLK opened at $0.76 on Friday. The firm has a market cap of $112.39 million, a PE ratio of -0.65 and a beta of 0.82. The firm's fifty day moving average is $1.31 and its 200-day moving average is $0.70. Oncobiologics has a 52 week low of $0.16 and a 52 week high of $3.39.

Oncobiologics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.97 million. Sell-side analysts forecast that Oncobiologics will post -0.49 EPS for the current year.

Key Headlines Impacting Oncobiologics

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
• Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
• Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
• Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
• Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
• Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement

Insider Buying and Selling

In other news, Director Faisal Ghiath Sukhtian acquired 95,398 shares of the firm's stock in a transaction dated Wednesday, July 29th. The stock was bought at an average cost of $1.05 per share, for a total transaction of $100,167.90. Following the completion of the transaction, the director directly owned 220,972 shares in the company, valued at $232,020.60. This represents a 75.97% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ghiath M. Sukhtian bought 8,539,709 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were purchased at an average cost of $0.59 per share, with a total value of $5,038,428.31. Following the purchase, the director directly owned 22,092,068 shares of the company's stock, valued at $13,034,320.12. The trade was a 63.01% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 11,189,359 shares of company stock worth $7,662,666 in the last 90 days. Corporate insiders own 1.80% of the company's stock.

Institutional Trading of Oncobiologics

Large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its position in shares of Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock worth $39,000 after acquiring an additional 21,941 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after purchasing an additional 25,351 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after purchasing an additional 44,063 shares in the last quarter. 11.20% of the stock is currently owned by institutional investors and hedge funds.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics' research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source